Table 1 Selected studies pooling 205 patients for systematic review and meta-analysis and display of main patient characteristics
First author | Year publ. | Setting | N | Gender, % men | Age, median (range) | Clear cell type, % | Previous nephrectomy | Poor risk percent | First-line targeted therapy | PRR | DCR | PFS (months) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xie | 2015 | Phase II | 85 | 72 % | 63 (41–85) | 100 % | 81 % | 24.4 %a | sunitinib | 15.3 % (11.2–23.9 %) | 70.6 % | 5.6 (4.1–6.7) |
Hainsworth | 2013 | Phase II | 55 | 76 % | 60 (41–82) | 100 % | 89 % | 29 %b | sunitinib (N = 39) or bevacizumab (N = 16) | 27 % (?-?) | 76 % | 7.5 (5.4–9.4) |
Sanchez | 2013 | Retrospective | 32 | 65 % | NA | 81 % | 74 % | 28.3 %c | sunitinib | NA | NA | 13 (9.0–17.0) |
Matrana | 2013 | Retrospective | 17 | 69 % | 65 (45–83) | 100 % | 89 % | 34 % (MSKCC) | sunitinib | NA | NA | 3.5 (1.0–15.5) |
Rautiola | 2013 | Retrospective | 14 | 61 % | 65 (40–82) | 90 % | 90 % | 19 %c | sunitinib | 43 % | 77 % | 11 (4.6–15.6) |
Al-Marrawi | 2013 | Retrospective | 14 | NA | 50 (44–78) | 92 % | 90 % | 17 %c | VEGF inhibitord | 0 % (0/2)e | NA | NA |